Enalare Secures BARDA Award Of $50M For ENA-001 In Drug Overdose
Eagle Pharmaceuticals Inc (NASDAQ: EGRX) announced that Enalare Therapeutics Inc secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority (BARDA).
In partnership with BARDA, ENA-001 is being developed in an intramuscular (IM) formulation for potential use in patients experiencing community drug overdose and as a potential medical countermeasure for mass casualty events.
The contract is awarded in stages based on the achievement of established milestones and deliverables and provides funding for further development of ENA-001.
The first phase of the contract, which provides approximately $6.0 million to complete activities through the initial Phase 1 study, coincides with grant support from the National Institute on Drug Abuse, part of the National Institutes of Health.
In August 2022, Eagle made an equity investment of $12.5 million in Enalare, with a commitment to another $12.5 million six months later and two potential follow-on contingent equity investments of $15 million.
Eagle also can acquire the remaining Enalare shares for $100-$175 million plus royalty rights.
Price Action: EGRX shares are up 1.86% at $27.60 on the last check Tuesday.
See more from Benzinga
X4 Pharma Highlights New Data Supporting Mavorixafor's Broad Potential In Chronic Neutropenia
Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.